Ixazomib (Ninlaro®)

Assessment Status Assessment process complete
Drug Ixazomib
Brand Ninlaro®
Indication In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Assessment Process
Rapid Review Commissioned 23/11/2016
Rapid review completed 16/01/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 23/01/2017
Pre-submission consultation with Applicant 06/02/2017
Full submission received from Applicant 01/06/2017
Preliminary review sent to Applicant 04/08/2017
NCPE assessment re-commenced 31/08/2017
Factual accuracy sent to applicant 20/11/2017
NCPE assessment re-commenced 04/12/2017
Applicant factual accuracy check 07/12/2017
NCPE assessment re-commenced 12/12/2017
NCPE assesment completed 18/12/2017
NCPE assessment outcome Reimbursement not recommended.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations – December 2018.